ARTA
ALDR

A.R.T. Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

A.R.T. Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31,739
Closed -$528K – 1850
2018
Q3 		$528K Sell
31,739
-54,088
-63% -$978K 0.02% 839
2018
Q2 		$1.36M Sell
85,827
-16,100
-16% -$245K 0.06% 506
2018
Q1 		$1.29M Buy
101,927
+24,800
+32% +$359K 0.05% 557
2017
Q4 		$883K Sell
77,127
-12,600
-14% -$141K 0.04% 672
2017
Q3 		$1.1M Buy
+89,727
New +$936K 0.06% 491
2015
Q1 		– Sell
-37,567
Closed -$1.09M – 1818
2014
Q4 		$1.09M Buy
37,567
+1,970
+6% +$35.4K 0.04% 611
2014
Q3 		$451K Buy
+35,597
New +$538K 0.02% 791

Other funds holding ALDR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

A.R.T. Advisors's ALDR Position: Q4 2018 in Review

A.R.T. Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 31,739 shares — an estimated $528K sold.

A.R.T. Advisors first reported a position in ALDR in Q3 2014 and held it in 7 quarters. The position peaked at $1.36M in Q2 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

  • A.R.T. Advisors reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 31,739 Alder Biopharmaceuticals shares in Q4 2018, an estimated $528K.
  • A.R.T. Advisors first reported a position in Alder Biopharmaceuticals in Q3 2014 and held it in 7 quarters.
  • A.R.T. Advisors's Alder Biopharmaceuticals position peaked at $1.36M in Q2 2018.
  • 124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.